CL2013002608A1 - Uso de dosis bajas de il -2 para tratar transtornos inflamatorios y relacionados con la autoinmunidad - Google Patents

Uso de dosis bajas de il -2 para tratar transtornos inflamatorios y relacionados con la autoinmunidad

Info

Publication number
CL2013002608A1
CL2013002608A1 CL2013002608A CL2013002608A CL2013002608A1 CL 2013002608 A1 CL2013002608 A1 CL 2013002608A1 CL 2013002608 A CL2013002608 A CL 2013002608A CL 2013002608 A CL2013002608 A CL 2013002608A CL 2013002608 A1 CL2013002608 A1 CL 2013002608A1
Authority
CL
Chile
Prior art keywords
related disorders
low doses
treat inflammatory
autoimmune related
autoimmune
Prior art date
Application number
CL2013002608A
Other languages
English (en)
Inventor
David Klatzmann
David Saadoun
Patrice Cacoub
Michele Rosenzwajg
Eliane Piaggio
Gilbert Bensimon
Claude Bernard
Original Assignee
Assistence Publique Hopitaux De Paris
Univ Pierre Et Marie Curie Paris 6
Imserm Institut National De La Sante Et De La Rech Medicale
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57232567&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2013002608(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Assistence Publique Hopitaux De Paris, Univ Pierre Et Marie Curie Paris 6, Imserm Institut National De La Sante Et De La Rech Medicale filed Critical Assistence Publique Hopitaux De Paris
Publication of CL2013002608A1 publication Critical patent/CL2013002608A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Virology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Communicable Diseases (AREA)
  • Reproductive Health (AREA)
  • Molecular Biology (AREA)
CL2013002608A 2011-03-11 2013-09-10 Uso de dosis bajas de il -2 para tratar transtornos inflamatorios y relacionados con la autoinmunidad CL2013002608A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161451663P 2011-03-11 2011-03-11
EP11305269 2011-03-11

Publications (1)

Publication Number Publication Date
CL2013002608A1 true CL2013002608A1 (es) 2014-05-30

Family

ID=57232567

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2013002608A CL2013002608A1 (es) 2011-03-11 2013-09-10 Uso de dosis bajas de il -2 para tratar transtornos inflamatorios y relacionados con la autoinmunidad
CL2015001241A CL2015001241A1 (es) 2011-03-11 2015-05-08 Uso de interleucina 2 (il-2) para tratar trastornos inflamatorios o relacionados con la autoinmunidad (div. sol. n° 2608-13)

Family Applications After (1)

Application Number Title Priority Date Filing Date
CL2015001241A CL2015001241A1 (es) 2011-03-11 2015-05-08 Uso de interleucina 2 (il-2) para tratar trastornos inflamatorios o relacionados con la autoinmunidad (div. sol. n° 2608-13)

Country Status (5)

Country Link
US (4) US9669071B2 (es)
JP (3) JP6416855B2 (es)
BR (1) BR112013023151A2 (es)
CL (2) CL2013002608A1 (es)
ES (1) ES2811624T3 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112013023151A2 (pt) 2011-03-11 2020-09-15 Assistance Publique - Hôpitaux De Paris interleucina-2 para uso no tratamento de desordem auto-imune, !muno-relacionada ou inflamatória e método para determinar se um regime ou dose de il-2 tem de ser modificado
RU2766157C2 (ru) 2011-06-01 2022-02-08 Интрексон Актобиотикс Н.В. Система полицистронной экспрессии для бактерий
JP6612258B2 (ja) * 2014-04-22 2019-11-27 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 自己免疫疾患の診断のための方法
WO2016025385A1 (en) 2014-08-11 2016-02-18 Delinia, Inc. Modified il-2 variants that selectively activate regulatory t cells for the treatment of autoimmune diseases
GB201515244D0 (en) * 2015-08-27 2015-10-14 Univ Birmingham Treatment of inflammatory disease or condition
JP7292877B2 (ja) * 2016-01-14 2023-06-19 イントレクソン・アクトバイオテイクス・エヌブイ １型糖尿病を処置するための組成物および方法
US20170204154A1 (en) 2016-01-20 2017-07-20 Delinia, Inc. Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
US11077172B2 (en) 2016-11-08 2021-08-03 Delinia, Inc. IL-2 variants for the treatment of psoriasis
CA3056630A1 (en) 2017-03-15 2018-09-20 Pandion Therapeutics, Inc. Targeted immunotolerance
CN111010866A (zh) 2017-05-24 2020-04-14 潘迪恩治疗公司 靶向免疫耐受性
US10174091B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
EP3927368A4 (en) 2019-02-20 2022-10-19 KSL Biomedical Inc. METHODS FOR PREDICTING AND MONITORING THE EFFECTIVENESS OF LOW-DOSE IL-2 AND HYDROXYCHLOROQUINE THERAPY IN AUTOIMMUNE DISEASES AND ITS LONG-TERM USE IN AUTOIMMUNE-RELATED DISORDERS
CN109999179A (zh) * 2019-05-08 2019-07-12 山东省分析测试中心 低剂量白介素2用于制备治疗阿尔茨海默病药物中的应用
AU2020279240A1 (en) 2019-05-20 2021-12-23 Pandion Operations, Inc. MAdCAM targeted immunotolerance
US20210059962A1 (en) * 2019-09-03 2021-03-04 Regen BioPharma, Inc. Stimulation of t regulatory cells by cannabidiol as a means of treating arthritis and autoimmunity
US20230256015A1 (en) * 2019-12-18 2023-08-17 Washington University Compositions and methods for treatment of headache disorders and neuropathic pain
AU2021207652B2 (en) 2020-01-14 2023-08-03 Synthekine, Inc. Biased IL2 muteins methods and compositions
US11981715B2 (en) 2020-02-21 2024-05-14 Pandion Operations, Inc. Tissue targeted immunotolerance with a CD39 effector
WO2022032040A1 (en) 2020-08-05 2022-02-10 Synthekine, Inc. Il2rb/il2rg synthetic cytokines
CA3204162A1 (en) 2021-01-11 2022-07-14 Robert Kastelein Compositions and methods related to receptor pairing
WO2024043975A1 (en) * 2022-08-25 2024-02-29 Board Of Regents Of The University Of Nebraska Induction and expansion of regulatory t cells

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63183538A (ja) * 1986-09-01 1988-07-28 Takeda Chem Ind Ltd 関節リウマチまたは全身性エリテマト−デスの改善，治療剤
EP0262802A3 (en) 1986-09-01 1990-01-31 Takeda Chemical Industries, Ltd. Medicament for the treatment or improvement of rheumatoid arthritis or systemic lupus erythematosus
US5466447A (en) 1988-06-29 1995-11-14 Amgen Inc. Method for treating psoriasis
WO1991014444A1 (en) 1990-03-19 1991-10-03 Brigham And Women's Hospital Treatment of cachexia with interleukin 2
US5466477A (en) 1993-11-08 1995-11-14 Hawkins Chemical, Inc. Preparation of process cheese using liquid sodium phosphate
FR2769505B1 (fr) 1997-10-10 2000-06-30 Michael Gerard Tovey Compositions de cytokines a administrer a la muqueuse buccale, et leurs utilisations
GB9724838D0 (en) 1997-11-26 1998-01-21 Franks Christopher R Compositions
WO2002078624A2 (en) 2001-03-30 2002-10-10 Mayo Foundation For Medical Education And Research Aerosol administration of interleukin-2 liposomes
ATE441420T1 (de) * 2002-12-02 2009-09-15 Innate Pharma Interleukin-2 und gamma delta t zellaktivator enthaltende zusammensetzungen und deren verwendungen
WO2005007121A2 (en) 2003-07-18 2005-01-27 Massachusetts Institute Of Technology Mutant interleukin-2(il-2) polypeptides
US20070098685A1 (en) 2005-01-19 2007-05-03 Brand Stephen J Methods and kits to treat chronic inflammatory immune diseases by administering a proteasome inhibitor and an interleukin 2 receptor agonist
ES2432141T3 (es) * 2005-01-27 2013-11-29 Novartis Vaccines And Diagnostics, Inc. Procedimientos para tratar carcinoma de células renales
AU2009224690B2 (en) 2008-03-13 2014-10-09 Biotest Ag Agent for treating disease
DE102008023820A1 (de) 2008-05-08 2009-11-12 Aicuris Gmbh & Co. Kg Mittel zur Behandlung und/oder Prophylaxe einer Autoimmunerkrankung und zur Bildung von Regulatorischen T-Zellen
WO2010049438A2 (en) 2008-10-30 2010-05-06 Innate Pharma Improved methods of using phosphoantigens for the treatment of diseases
WO2010085495A1 (en) 2009-01-21 2010-07-29 Amgen Inc. Compositions and methods of treating inflammatory and autoimmune diseases
CN102462837B (zh) 2010-11-19 2016-08-03 生物林格斯Ip有限公司 抗炎组合物
BR112013023151A2 (pt) 2011-03-11 2020-09-15 Assistance Publique - Hôpitaux De Paris interleucina-2 para uso no tratamento de desordem auto-imune, !muno-relacionada ou inflamatória e método para determinar se um regime ou dose de il-2 tem de ser modificado

Also Published As

Publication number Publication date
US20170304402A1 (en) 2017-10-26
CL2015001241A1 (es) 2015-08-14
US9669071B2 (en) 2017-06-06
US10293028B2 (en) 2019-05-21
US10765723B2 (en) 2020-09-08
JP6416855B2 (ja) 2018-10-31
US11559566B2 (en) 2023-01-24
BR112013023151A2 (pt) 2020-09-15
JP2017061551A (ja) 2017-03-30
US20210038691A1 (en) 2021-02-11
JP2021006591A (ja) 2021-01-21
JP2019014743A (ja) 2019-01-31
ES2811624T3 (es) 2021-03-12
US20190351023A1 (en) 2019-11-21
US20140004080A1 (en) 2014-01-02

Similar Documents

Publication Publication Date Title
CL2013002608A1 (es) Uso de dosis bajas de il -2 para tratar transtornos inflamatorios y relacionados con la autoinmunidad
CO6870033A2 (es) Compuestos terapéuticos y métodos de uso relacionados
CL2015003440A1 (es) Composiciones de arni contra tmprss6 y métodos para su uso
CO7020872A2 (es) Agentes de arn, composiciones y métodos de uso de los mismos para tratar enfermedades asociadas con transtiretina (ttr)
CO6900138A2 (es) Nuevos sulfóxidos de piperidino-dihidrotienopirimidina y su uso para tratar epoc y asma
CL2015000640A1 (es) Variantes de hppd y métodos de uso
CO6831975A2 (es) Inmunoconjugados, composiciones para prepararlos, métodos para prepararlos y uso
BR112013018877A2 (pt) composições farmacêuticas que compreendem anticorpos humanos para pcsk9
CO6900118A2 (es) Métodos para tratar el cancer por el uso de antagonistas de unión al eje pd-1e inhibidores de mek
BR112014013847A2 (pt) uso de dispositivos para tratar patologias da coluna vertebral
CL2014003017A1 (es) Uso de un heparinoide interactuando con pf4 para tratar efecto mielodepresivo
CO7030962A2 (es) Compuestos terapéuticamente activos y sus métodos de uso
CO7010834A2 (es) Compuestos terapéuticamente activos y sus métodos de uso
BR112013019734A2 (pt) composições e métodos para tratar inflamação crônica e doenças inflamatórias
CO7020907A2 (es) Inhibidores de quinurenina-3-monooxigenasa, composiciones farmacéuticas y métodos de uso de los mismos
CO6862148A2 (es) Composiciones transdérmicas de ibuprofeno y métodos de uso de las mismas
SMT201500057B (it) Uso della biotina per il trattamento della sclerosi multipla
EP2831047A4 (en) PFKFB3 INHIBITOR AND METHOD FOR USE AS THERAPEUTIC AGAINST CANCER
CO6811867A2 (es) Cannabinoides para uso en el tratamiento del dolor neuropático
BR112014016389A8 (pt) composições e uso das mesmas para o tratamento de distúrbios e doenças hepáticas
BR112013033968A2 (pt) uso de anticorpos agonistas anti-cd83 para tratamento de doenças autoimunes
DK2838539T3 (da) Østrogenderivater til anvendelse i behandlingen af neurologiske forstyrrelser
BR112013022883A2 (pt) aptâmero, composição farmacêutica, kit, uso de um aptâmero e coluna de aférese
BR112014003051A2 (pt) novas composições e uso das mesmas
IL240325A0 (en) Improvements related to the use of serial databases